Latanoprost
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Latanoprost: From Open-Angle Glaucoma to Primary Hereditary Glaucoma
One-Sentence Summary
Latanoprost is a PGF2α prostaglandin analogue whose established mechanism is lowering intraocular pressure via increased uveoscleral outflow, historically used for open-angle glaucoma and ocular hypertension. The TxGNN model predicts it may also be effective for Primary Hereditary Glaucoma, supported by 1 completed Phase 2 clinical trial and currently no published literature. The mechanistic link is direct (same drug class, same target physiology), but the evidence base remains narrow and safety documentation is incomplete.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not confirmed via Danish licence data (drug not marketed in Denmark); established pharmacological use is open-angle glaucoma / ocular hypertension |
| Predicted New Indication | Primary Hereditary Glaucoma |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L2 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for this drug record is not available (marked as a data gap). Based on the evidence pack’s own repurposing rationale, latanoprost is a PGF2α prostaglandin analogue known to lower intraocular pressure by increasing uveoscleral (trabecular) aqueous humour outflow — this is the standard treatment mechanism for primary open-angle glaucoma.
Primary hereditary glaucoma (including congenital/pediatric hereditary subtypes) shares the same core pathophysiology of elevated intraocular pressure, differing mainly in genetic/developmental origin of outflow obstruction rather than the downstream pressure-lowering target. Because latanoprost’s mechanism acts on aqueous outflow regardless of the underlying cause of elevated IOP, extending its use to hereditary glaucoma subtypes is mechanistically direct rather than a novel or speculative repurposing hypothesis.
This is reinforced by the one available clinical trial, which directly compared a prostaglandin analogue (latanoprost) against a carbonic anhydrase inhibitor (dorzolamide) specifically in a pediatric/hereditary glaucoma population — indicating this application has already been explored clinically, not merely inferred by the model.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01527682 | Phase 2 | Completed | 37 | Assessed ocular hypotensive effect and safety of latanoprost vs. dorzolamide (carbonic anhydrase inhibitor) in patients with primary pediatric glaucoma refractory to surgical procedures. |
Literature Evidence
Currently no related literature available.
Denmark Market Information
No marketing authorisation is currently registered for this drug in Denmark (market status: Not marketed; 0 licences on file).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Key warnings, contraindications, and drug-drug interaction data are not currently available in this evidence pack — including the TFDA label/warning data required for S1 safety screening, which is flagged as a blocking data gap.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic case is strong and direct — latanoprost’s IOP-lowering action via increased aqueous outflow applies to hereditary glaucoma subtypes just as it does to open-angle glaucoma — and one completed Phase 2 trial already supports this specific population. However, evidence rests on a single trial with no corroborating literature, and safety documentation (warnings, contraindications, DDI) is currently absent, so unrestricted advancement is not yet warranted.
To proceed, the following is needed:
- Danish/EU-approved SmPC warnings and contraindications (currently a blocking data gap)
- Confirmed mechanism of action and original approved indication documentation for this drug record
- Additional literature or trials specific to hereditary/congenital glaucoma subtypes to corroborate the single existing trial
- Drug-drug interaction data (current query returned no results)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.